Contents

Current Pharmaceutical Design, Volume 7 - Number 16

Preface

, 7(16): ii

Elke S. Bergmann-Leitner


DOI: 10.2174/1381612013397195




New Strategy Developments in Brain Tumor Therapy

, 7(16): 1553 - 1580

A.A. Brandes, U. Basso, L.M. Pasetto and M. Ermani


DOI: 10.2174/1381612013397221




Ras Signaling Pathway Proteins as Therapeutic Targets

, 7(16): 1581 - 1594

Alex A. Adjei


DOI: 10.2174/1381612013397258




A Prevention Strategy for Circumventing Drug Resistance in Cancer Chemotherapy

, 7(16): 1595 - 1614

Gerald D. Frenkel and Paula B. Caffrey


DOI: 10.2174/1381612013397186




Lipid Messengers as Targets for Antiangiogenic Therapy

, 7(16): 1615 - 1626

E. G. Robert and J. D. Hunt


DOI: 10.2174/1381612013397203




Rationally Designed Anti-mitotic Agents with Pro-Apoptotic Activity

, 7(16): 1627 - 1639

Fatih M. Uckun


DOI: 10.2174/1381612013397177




Nucleic Acid for the Treatment of Cancer: Genetic Vaccines and DNA Adjuvants

, 7(16): 1641 - 1667

W. W. Leitner, P. Hammerl and J. Thalhamer


DOI: 10.2174/1381612013397249




Early Development of Cyclin Dependent Kinase Modulators

, 7(16): 1669 - 1687

K.K. Roy and E.A. Sausville


DOI: 10.2174/1381612013397230




License to Kill Tumors: How Much Hope is Justified for Trail?

, 7(16): 1689 - 1701

S. Frank and A.D. Ebert


DOI: 10.2174/1381612013397212




Webmaster Contact: info@benthamscience.org
Copyright © 2018 Bentham Science